Virksomhedsstatus | NORMAL. |
Sidst opdateret den 17.04.2018 og
angivet som gældende fra 17.04.2018 (2314
dage). |
Ingen historik.
Branche | Engroshandel med medicinalvarer og sygeplejeartikler (464610). |
Sidst opdateret den 17.04.2018 og
angivet som gældende fra 17.04.2018 (2314
dage). |
Ingen historik.
Revisionfravalgt | false. |
Sidst opdateret den 21.06.2018 og
angivet som gældende fra 19.06.2018 (2251
dage). |
Historik | Start | Stop |
---|
false | 19.06.2018 | |
true | 17.04.2018 | 18.06.2018 |
Kontaktoplysninger | info@oresundpharma.com. |
Sidst opdateret den 12.06.2019 og
angivet som gældende fra 12.06.2019 (1893
dage). |
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Navne | Øresund Pharma ApS. |
Sidst opdateret den 21.06.2018 og
angivet som gældende fra 19.06.2018 (2251
dage). |
Historik | Start | Stop |
---|
Øresund Pharma ApS | 19.06.2018 | |
Øresund Pharma IVS | 17.04.2018 | 18.06.2018 |
Binavne | Oresund ApS. |
Sidst opdateret den 21.06.2018 og
angivet som gældende fra 20.06.2018 (2250
dage). |
Historik | Start | Stop |
---|
Oresund ApS | 20.06.2018 | |
Oresund Pharma ApS | 20.06.2018 | |
Oresund IVS | 17.04.2018 | 19.06.2018 |
Oresund Pharma IVS | 17.04.2018 | 19.06.2018 |
Tegningsregel | Virksomheden tegnes af en direktør alene. |
Sidst opdateret den 17.04.2018 og
angivet som gældende fra 17.04.2018 (2314
dage). |
Fortolkning
(1 tegningsmulighed)
| 1 direktør |
Ingen historik.
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:BDO Statsautoriseret revisionsaktieselskab
Revisionsvirksomhedens CVR-nr.:20222670
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):Basis for Opinion
Grundlag for konklusion
We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the “Auditor’s Responsibilities for the Audit of the Financial Statements” section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), together with the ethical requirements that are relevant to our audit of the financial statements in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion.
Konklusion (revision):We have audited the Financial Statements of Øresund Pharma ApS for the financial year 1 January - 31 December 2023, which comprise income statement, Balance Sheet, statement of changes in equity, notes and a summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.
In our opinion, the Financial Statements give a true and fair view of the assets, liabilities and financial position of the Company at 31 December 2023 and of the results of the Company's operations for the financial year 1 January - 31 December 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on Management Commentary
Management is responsible for Management Commentary.
Our opinion on the Financial Statements døs not cover Management Commentary, and we do not express any form of assurance conclusion thereon.
In connection with our audit of the Financial Statements, our responsibility is to read Management Commentary and, in doing so, consider whether Management Commentary is materially inconsistent with the Financial Statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.
Moreover, it is our responsibility to consider whether Management Commentary provides the information required under the Danish Financial Statements Act.
Based on the work we have performed, we conclude that Management Commentary is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of Management Commentary.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Hjemmeside | www.oresundpharma.com. |
Sidst opdateret den 12.06.2019 og
angivet som gældende fra 12.06.2019 (1893
dage). |
Ingen historik.